Kornimate/medical-research-clean huggingface dataset:
maternal voice and quantitative eeg (qeeg)

Conditions: Prematurity; Development Delay; Premature Birth

Summary: a short-term randomized, blinded placebo-controlled trial, in premature infants in the neonatal intensive care unit (nicu) at 33-35 weeks post-conceptional age, of recorded maternal voice on quantitative eeg (spectral power density) as a marker of development.

this will be a randomized placebo-controlled clinical trial. infants consented to participate will be randomized into the intervention arm or non-intervention arm by sealed unmarked envelope. all consented participants will have an initial eeg of 60-90 minutes duration, performed at 32 5/7 - 32 6/7 weeks (and after 72 hours of life). starting at 33 0/7 weeks corrected gestational age (regardless of birth gestation), eligible subjects will proceed with randomized intervention or placebo for a 2-week (14 day) intervention period. all infants will receive a 2nd eeg of 30-60 minutes duration, performed between 35 0/7 - 35 6/7 weeks corrected gestational age, following completion of either the intervention or non-intervention arm (with the goal of the 2nd eeg occurring within 48 hours of infants having completed the intervention vs. non-intervention arm). eeg technician and all persons reviewing, pruning and analyzing data from the qeeg will be blinded to whether the infant was in the intervention or the non-intervention arm.

Eligibility criteria:
inclusion criteria: * infants born at 28 0/7 - 32 3/7 weeks gestation (to allow for infants born at 32 3/7 weeks to have initial eeg performed after 72 hours of life and prior to initiating intervention or non-intervention arm at 33 0/7 weeks gestation) * mother available to provide voice recording, and have ability to converse and read in english (as the scripted content for the intervention will be provided in english) exclusion criteria: * infant with critical congenital cardiac disease * infant with chromosomal anomaly or inborn error of metabolism * infant with known neurologic disorder/abnormality - including hypoxic-ischemic encephalopathy (hie), intraventricular hemorrhage (ivh), periventricular leukomalacia (pvl), seizure activity, anatomic abnormality * infant receiving antiepileptic or sedation medications prior to eeg * initial eeg abnormal with epileptiform activity or not consistent with corrected gestational age * mother not available to provide voice recording in english * unable to obtain consent from mother due to maternal health issues following delivery (such as mother requiring intubation or sedation following delivery * mothers who are prisoners (as the study team would like to have continuing communication during the study period as needed) * mothers who are \<18 years of age will not be approached for consent * any mother that is not able to consent due to having a legal representative will not be approached for consent * any infant that is planned to be placed for adoption, is in foster care or is a ward of the state

Keywords: quantitative eeg spectral density analysis at risk for cognitive delay premature birth 28-32 weeks gestation
effect of deep brain stimulation on lower urinary tract function

Conditions: Movement Disorder; Urinary Tract Disease

Summary: the precise mechanisms underlying cerebral regulation of lower urinary tract (lut) function are still poorly understood. patients with deep brain stimulation (dbs) offer the unique opportunity to investigate the role of different cerebral centers on lut function. we hypothesize that dbs has a significant effect on lut function and that these effects depend on the specific stimulated cerebral center.


Eligibility criteria:
inclusion criteria: * patients with deep brain stimulation (dbs) exclusion criteria: * pregnancy * age \<18 years

Keywords: deep brain stimulation urodynamics
quantiferon-tb gold in the assessment of latent tb in patients candidate to treatment or treated with tnfα antagonists

Conditions: Rheumatoid Arthritis; Spondylarthritis; Tuberculosis

Summary: the purpose of this study is to evaluate the value of quantiferon-tb gold (qft-g) assay in the screening for latent tuberculosis infection (ltbi) in rheumatologic patients due to start or on treatment with tnfα antagonists. the results of qft-g will be compared to tuberculin skin testing (tst) and correlated to clinical and demographic data. the study hypothesis is that the inclusion of qtf-g in the screening strategy will allow a more accurate assessment of ltbi infection.

treatment with tnfα antagonists is associated with an increased risk of active tuberculosis. screening for ltbi and adherence to published guidelines have been shown to greatly decrease the risk of active tuberculosis. however, the best screening strategy is still object of debate. the validity of tst in patients on immunosuppressive treatment has been questioned. recently, interferon-γ assays based on rd1-specific antigens have shown to cause less confounding by bcg vaccination and from most non-tuberculosis mycobacteria than tst, and have shown improved accuracy over tst in several settings. however, data on their use in rheumatologic patients are limited, and their superiority in patients on immunosuppressive treatment is unclear since indeterminate results may limit their clinical usefulness in this setting. purpose of the study is to investigate the added value of the inclusion of qtf-g assay in the screening strategy of ltbi in rheumatologic patients before and during treatment with tnfα antagonists. the study will compare the results of tst with the results of qft-g assay in rheumatologic patients being evaluated for treatment with anti-tnfα agents or already on treatment with anti-tnfα agents. the rate of positive and negative results of the two test will be compared, end results correlated to clinical and demographic variables.

Eligibility criteria:
inclusion criteria: * patients with rheumatological diseases being evaluated for treatment with tnfα antagonists or on treated with tnfα antagonists exclusion criteria: * unable to sign informed consent * known hypersensitivity to tuberculin
a single-cell transcriptome study in patients with non-hodgkin's lymphoma

Conditions: Non Hodgkin Lymphoma

Summary: using single-cell rna sequencing, this study will explore the heterogeneity of lymphoma inside and outside the lymph node, identify tumor specific molecular markers and cell subgroups, explore the differences in tumor microenvironment composition, and provide a basis for diagnosis and precision treatment.

in recent decades, the incidence of lymphoma has been increasing year by year in the world. non-hodgkin lymphoma accounts for about 90% of lymphoma, of which the classification is complex and the efficacy is poor compared to hodgkin's lymphoma. non-hodgkin's lymphoma is often associated with the extra nodal involvement, and according to literature, extra nodal lymphoma accounts for 1/3 to 1/2 of all non-hodgkin lymphomas. compared with non-hodgkin's lymphoma without extra nodal involvement, the prognosis of lymphoma with extra nodal involvement was relatively poor. the recurrence rate was higher, and its incidence, histology type, clinical staging and so on all had their own characteristics. tumor cells depend to some extent on the interaction with non-tumor cells and matrix components of the tumor microenvironment to maintain survival and proliferation. in addition, the non tumor cells and matrix components can mediate immunosuppressive action to promote tumor escape from immunosurveillance, resulting in disease progression. at the same time, more and more data show that the tumor microenvironment plays a key role in the development of tumor resistance. the cellular composition and spatial properties of the tumor microenvironment show significant heterogeneity, depending on a number of factors, including subtypes of lymphomas and extra nodal sites of lymphomas. studying the tumor microenvironment will provide rationale for more precise target therapy. through single-cell rna sequencing, this study hopes to identify the heterogeneity of nodal and extra nodal lymphoma cells, to understand the differences in tumor microenvironment, and to provide a basis for diagnosis and precision treatment. there are new target drugs for different antigen targets. but patients may not be sensitive to a certain drug, and the drug is often expensive, resulting in increased financial burden on patients without efficacy. therefore, the research for biomarkers to predict patient efficacy and prognosis is particularly important. the treatment efficacy of patients with relapsed lymphoma is often not good, so the prediction and treatment of patients with high-risk of relapsing is a clinical significant problem. on the basis of single-cell transcriptomics, this study hopes to find biomarkers for predicting the relapse of lymphoma and provide new ideas for clinical diagnosis and treatment.

Eligibility criteria:
inclusion criteria: * patients with pathological confirmed diagnosis of non-hodgkin's lymphomas. * patients with both lymph node and extra nodal involvement, or patients at high risk of relapse, or patients receiving a novel target drug treatment.
marijuana in combination with opioids in palliative and hospice patients

Conditions: Pain

Summary: study objectives: primary reduction of pain and reduction in overall opioid utilization. secondary improvement in overall patient well being, weight stabilization with increased appetite, improved oxygen saturation, improvement or prevention of nausea and vomiting. study rationale: to determine optimum use and dosing of medical marijuana (cbd:thc) for pain and symptom management. study population: this study specifically will enroll cancer and non-cancer patients as a primary diagnosis suffering from pain and having a terminal illness (defined as having less than 6 months to live) requiring end of life care.

primary endpoint: primary reduction of pain and reduction in overall opioid utilization as evidenced by overall reduction in numeric pain scores and mme (morphine milliequivalents) secondary and exploratory endpoints:secondary improvement in overall patient well being, weight stabilization with increased appetite, improved oxygen saturation, improvement or prevention of nausea and vomiting. endpoints evaluation will be based on change from baseline using the modified edmonton assessment scale. study design: this will be an open-label study. patients will choose to participate in a marijuana adjuvant treatment group, receiving marijuana in combination with standard opioid therapy. subject number: minimum 66 patients treatment duration: minimum 5 days duration of follow up: patients' initial opioid dose, dosing schedule and numeric pain score will be recorded. for the duration of the study (at least five days) changes in opioid doses and numeric pain scores will be tracked daily. marijuana will be administered to the patient via oral route three times daily for at least five days. patients will receive standardized cbd:thc product provided by nida. on admission to the study, a modified edmonton symptom assessment scale to quantify baseline appetite, depression, nausea, vomiting, overall well-being, and anxiety. data tracking: primary objective tracking will include average numeric pain scores and number of opioid dosage increases and average daily opioid amount (mg equivalents of morphine). secondary objectives include weight, appetite, n/v, o2 saturation, self-reported data points from the modified edmonton assessment scale.

Eligibility criteria:
inclusion criteria: * age \> 18 * alert adults * requiring opioids for pain management (routine) * cancer diagnosis or non-cancer diagnosis as their terminal illness exclusion criteria: * pregnant women * age \< 18 * minimally or unresponsive patients unable to take oral medications * agitated combative patients

Keywords: pain management terminally ill
the protein disrupted in schizophrenia 1 (disc1) as a novel biomarker for cardiac disease

Conditions: Heart Diseases; Heart; Functional Disturbance; Schizophrenia

Summary: to study the association between disc1 rna expression levels and cardiac function in patients with schizophrenia.

potential participants interested in the study will be screened for eligibility. those who meet the eligibility criteria will be informed about the study, the expected investigations and its potential risks. all participants giving written informed consent will be enrolled into the study. participants will be interviewed, given questionnaires, have blood and/or skin samples and clinical parameters taken. cardiac function parameters will be measured using electrocardiography, echocardiography and magnetic resonance imaging.

Eligibility criteria:
inclusion criteria: * patients with icd-10 schizophrenia, schizotypal or delusional disorders (f20 to f29) * both inpatient and outpatient * capable of giving informed consent exclusion criteria: * current or previous diagnosis of cancer * current or previous treatment with chemotherapy * current pregnancy * mothers less than 6 months post-partum

Keywords: disrupted in schizophrenia 1 disc1 cardiac biomarker
german epicardial collateral cto registry

Conditions: Coronary Artery Disease; Chronic Total Occlusion; Percutaneous Coronary Intervention

Summary: the epic registry is an observational multicentre registry evaluating the technical feasibility of retrograde cto-pci using epicardial collateral connections. it will evaluate the frequency, effectiveness, safety and outcomes of patients who underwent cto-pci using this approach. the epic registry retrieves data from cto centres across germany.

the epic registry is the first german-wide observational multicentre registry evaluating the technical feasibility, clinical success and safety of retrograde cto-pci using epicardial collateral connections. the epic registry retrieves data from cto centres across germany. all patients will be followed-up to 30 days after inclusion.

Eligibility criteria:
inclusion criteria: * all patients undergoing retrograde cto-pci using epicardial collateral connections during daily clinical practice. exclusion criteria: * none.
effecti̇veness of pulsed ultrasound treatment on patients with bell's palsy

Conditions: Bell Palsy

Summary: bell's palsy (idiopathic facial palsy) is the most common peripheral lesion of the cranial nerves and the most common mono-neuropathy. therapeutic ultrasound (us) is among the commonly used physical modalities for treating musculoskeletal disorders. the effects of us are due to alteration of cell membrane activity, vascular wall permeability and facilitation of tissue healing. the aim of this study is to investigate the effect of pulsed us treatment in patients with bell's palsy when added to superficial heating, massage and exercise therapies.

in this double -blind, randomized placebo-controlled trial, 32 patients (aged 18-65 years) diagnosed as idiopathic facial palsy with appropriate criteria were included. all patients were evaluated with motor nerve conduction studies and electromyography at 3-4 weeks after the onset of paralysis and 3 months after the treatment. paralytic side frontalis and orbicularis oris muscles were used for electrophysiological analysis. electrophysiological examinations were performed by an experienced electromyographer who was blind to the patient's treatments. patients were separated into two groups as group 1 (pulsed ultrasound therapy) and group 2 (sham). both groups were undergone to a conservative treatment program (20 min hot pack, massage 20 min and facial expression exercises) for 3 weeks, 5 days a week. in group 1 pulsed us treatment (frequency: 1000 khz, intensity: 0.5w/cm2, on-off ratio: 1:2, duration 5 min) were applied to the paralyzed facial muscles. the patients in group 2 received exactly the same procedure as the treatment group, except that the power switch was off. all treatments were applied for 5 days a week for 3 weeks by the same 5-cm2 head us device (enraf-nonius sonopuls 434) and the same physiotherapist. patients were assessed at baseline, after last session, and 3 months after the treatment. sunnybrook facial grading system, house brackmann facial grading system and facial disability index and electrophysiologic parameters were used for outcome evaluation.

Eligibility criteria:
inclusion criteria: * aged 18-65 years * clinically diagnosed as bell's palsy by an ear nose and throat specialist. exclusion criteria: * central nervous system pathology * recurrent bell's palsy * diabetes mellitus * contraindications of ultrasound treatment * active infection * cancer * pregnancy * lactation * open wound around application area

Keywords: bell's palsy facial paralysis pulsed ultrasound
a study to evaluate seroprevalence and seroconversion of antibodies to adeno-associated virus (aav) in patients with hemophilia a

Conditions: Hemophilia A

Summary: to quantify the seroprevalence of antibodies to aav5, aav6, and aav8 and the seroconversion rate over varying follow-up intervals in subjects with hemophilia a

this is a single-center, decentralized, patient-centered, prospective, observational study utilizing biospecimen samples collected from hemophilia a subjects across the united states to evaluate and characterize seroprevalence and the rate of seroconversion of antibodies against aav serotypes and exploratory vectors, and to investigate the associated factors that may influence the vector titers. relevant medical findings will also be collected from the subject, as well as symptoms related to hemophilia a. the collection of medical history may include major illnesses, diagnoses, and surgeries.

Eligibility criteria:
inclusion criteria: * subjects diagnosed with hemophilia a * subjects aged 18years or over at time of entry exclusion criteria: * currently participating in an interventional study of any investigational product, device or procedure. * subjects who have been previously treated with aav vector gene therapy
using handtutor with traumatic hand injuries: characterizing the system

Conditions: Hand Injuries

Summary: handtutor is a computerized system designed to evaluate and rehabilitate hand function. it is composed of a glove with optic sensors detecting the movements of the wrist and the fingers with a biofeedback software designed to evaluate and then to exercise the hand movements through supplying a variety of computer graphic patterns. the handtutor has been used and tested with a stroke population, and it seems potential to be used with hand injuried population. as a first step, it is important to investigate the characteristics of the system and how it is matching the hand injuried population. the purpose if this study is to characterize the handturor system and the focused objectives are: 1. to examine the test-retest reliability of the system when measuring the range of motion (rom) of the the fingers among healthy people (control group). 2. to examine the correlation between the rom measured by the handtutor and the rom measured by conventional assessment tools (goniometer). 3. to examine the ability of the system to distinguish between healthy people and hand injured people. 4. to examine the correlation between the performance in the handtutor (in the games part), and the performance in functional activities. 5. to examine the participants feedback for using the handtutor (degree of enjoyment).


Eligibility criteria:
inclusion criteria: * hand injuries causing a disfunction of one finger or more of the fingers 2nd-5th. * six weeks at least after the injury/surgery. * allowed to exercise their fingers with no contraindications according to the orthopedic surgeon instructions. * with no open wounds. exclusion criteria: * peripheral nerves injuries. * digital nerves injuries. * sensation problems. * crps-complex regional pain syndrome. * cognitive impairments. * head trauma.

Keywords: finger fractures tendon injuries soft tissue injuries
atorvastatin in the treatment of mandibular degree ii furcation defects

Conditions: Chronic Periodontitis

Summary: abstarct background: atorvastatin is an inhibitor of 3-hydroxy-2-methyl-glutaryl coenzyme a reductase. lately, it has shown to have anti-inflammatory and bone stimulatory effects. the aim of the current study is to explore the effectiveness of 1.2% atorvastatin (atv) as an adjunct to scaling and root planning (srp) in the treatment of mandibular degree ii furcation defects. method: a total of sixty subjects were randomly assigned to two treatment groups. 1. srp plus placebo gel 2. srp plus 1.2% atv gel. clinical parameters like probing depth (pd), relative vertical clinical attachment level (rvcal) , relative horizontal clinical attachment level (rhcal), modified sulcus bleeding index (msbi) and site specific plaque index were recorded at baseline and then at 3, 6 and 9 months. the radiological assessment of bone defect fill was done at 6 and 9 months, using a computer-aided software.

two groups were made. one was delivered with atv after srp, the other was delivered with placebo gel after srp.

Eligibility criteria:
inclusion criteria: * lower first molars demonstrating a probing pocket depth of 5 mm and horizontal probing depth of 3 mm following phase 1 therapy, with furcation defects (degree ii) present bucally in asymptomatic, vital lower first molars, with a furcation radiolucency on a periapical radiograph of the molars. exclusion criteria: * patients with systemic diseases like cardiovascular disease * diabetes or hiv infection or on medications like corticosteroids which may impede the healing in periodontal tissues. * pregnant/lactating females * tobacco users * alcoholics * patients with unsatisfactory oral hygiene (plaque index greater than 1.5) * teeth having gingival recession, caries involving pulp, intrabony defect present interproximally, grade 2/3 mobility * furthermore, patients allergic to atv or other statins or those taking atv/other statins systemically were excluded.
gia in cascade testing

Conditions: Genetic Predisposition

Summary: the objective of this pilot study is to evaluate the feasibility and acceptability of gia in sharing genetic test results with family members. to determine the utility of gia in sharing information. to determine the impact of gia on downstream cascade testing rates.

chatbots, also known as conversation agents, are programs designed to have interactive conversations with humans. while traditionally used in sectors such as online gaming and customer service, chatbots have made their way into a number of industries including healthcare and have shown promise in areas such as managing anxiety/depression, weight loss, and medication adherence. gia (genetic information assistant) is a chatbot specifically designed as a tool for patients to use for disseminating genetic results, education, and genetic counseling resources to their family members after they themselves receive a positive result. patients receive a secure gia link from their provider and then are able to send their relatives the link to gia through texting, email, and/or facebook messenger. once a relative clicks on the provided link, gia's platform is structured as a decision tree, allowing family members to construct a personalized conversation about their family member's test results. this can be done either on a smartphone or computer. gia provides basic genetics education and risk assessment and connects family members with local genetic counseling resources to continue this conversation and/or go forward with genetic testing. at the end of the conversation, the family member has the option of having a transcript sent to them via email for their reference. the objective of the current study is to evaluate the application of gia for cascade testing in newly identified high risk breast and gynecologic mutation carriers.

Eligibility criteria:
inclusion criteria: * age ≥ 18 * undergoing genetic testing at uva for a personal or family history of breast or gynecologic cancers in cancer genetics. exclusion criteria: * not receiving treatment at uva * not english literate * unable to provide consent

Keywords: genetic counseling genetic testing